Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5679866 | 0.80 | KMT2A (0.74) | ALDH1A1KMT2AMEN1SIGMAR1GAA | |
| SCHEMBL2236754 | 0.78 | KMT2A (0.72) | ALDH1A1KMT2AMEN1SIGMAR1GAA | |
| SCHEMBL8878994 | 0.77 | FNTA (0.51) | ALDH1A1KMT2AMEN1SIGMAR1GAA | |
| SCHEMBL3624308 | 0.76 | KMT2A (0.69) | ALDH1A1KMT2AMEN1SIGMAR1KDM4E | |
| SCHEMBL8325065 | 0.76 | KMT2A (0.71) | ALDH1A1KMT2AHPGDMEN1SIGMAR1 | |
| SCHEMBL30118954 | 0.76 | KMT2A (0.71) | ALDH1A1KMT2AHPGDMEN1SIGMAR1 | |
| SCHEMBL14826381 | 0.76 | RORC (0.69) | ALDH1A1KMT2AHPGDMEN1GAA | |
| SCHEMBL8875087 | 0.73 | FNTA (0.52) | ALDH1A1KMT2AMEN1SIGMAR1GAA | |
| SCHEMBL3456960 | 0.73 | KMT2A (0.61) | ALDH1A1KMT2AMEN1SIGMAR1KDM4E | |
| SCHEMBL8873556 | 0.73 | FNTA (0.52) | ALDH1A1KMT2AMEN1SIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100248365-A1 | GANGLIOSIDE BIOSYNTHESIS MODULATORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100248365-A1 | GANGLIOSIDE BIOSYNTHESIS MODULATORS | UGCG, MAGT1, STT3B | ALDH1A1 2578/4885KMT2A 1738/4885HPGD 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.